Oxford BioDynamics PLC 2025 AR2
The report highlights Oxford BioDynamics Plc's progress in commercialising its EpiSwitch precision medicine tests, with orders for the Prostate Screening EpiSwitch (PSE) test more than doubling to approximately 1,900. The company expanded its strategic partnership with Google Cloud to launch the EpiSwitch Orion cloud platform, migrating its 3D genomics database. Financially, clinical test revenue increased by 168% to £1.1m, while the operating loss was reduced to £11.1m. Post-year end, the company successfully raised £7m to fund its ongoing turnaround plan and developed a breakthrough diagnostic test for Chronic Fatigue Syndrome.
Company: Oxford BioDynamics PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 129
Back to company
Oxford BioDynamics PLC
Annual Report And Accounts
The report highlights Oxford BioDynamics Plc's progress in commercialising its EpiSwitch precision medicine tests, with orders for the Prostate Screening EpiSwitch (PSE) test more than doubling to approximately 1,900. The company expanded its strategic partnership with Google Cloud to launch the EpiSwitch Orion cloud platform, migrating its 3D genomics database. Financially, clinical test revenue increased by 168% to £1.1m, while the operating loss was reduced to £11.1m. Post-year end, the company successfully raised £7m to fund its ongoing turnaround plan and developed a breakthrough diagnostic test for Chronic Fatigue Syndrome.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Oct 1, 2024 - Sep 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees